Cost analysis of bivalirudin versus reference anticoagulants without GP IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention for acute coronary syndrome in routine clinical practice. Pompidou registry. [electronic resource]
Producer: 20131209Description: 89-94 p. digitalISSN:- 1768-3181
- Acute Coronary Syndrome -- economics
- Aged
- Aged, 80 and over
- Anticoagulants -- economics
- Antithrombins -- economics
- Cost-Benefit Analysis
- Drug Costs
- Female
- Heparin -- economics
- Hirudins -- economics
- Hospitals, University
- Humans
- Length of Stay -- economics
- Male
- Middle Aged
- Paris
- Peptide Fragments -- economics
- Percutaneous Coronary Intervention
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Prospective Studies
- Recombinant Proteins -- economics
- Registries
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.